Fluidigm Reports Preliminary Q4 Revenues of $21M | GenomeWeb

NEW YORK (GenomeWeb News) — Fluidigm said today that it expects total revenue for the fourth quarter of 2013 to be approximately $21 million, beating consensus analyst estimates of $19.5 million and representing a 34 percent spike compared to Q4 2012 revenues of $15.7 million.

Based on preliminary, unaudited financial data, Fluidigm said that it expected Q4 instrument revenue to be approximately $12 million and consumables revenue to be approximately $8.5 million compared to $9.6 million and $5.8 million, respectively, in the same quarter last year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: parent-of-origin effects, framework to uncover clinically important mutations from whole genome sequence data, and more.

A survey of Cincinnati schoolchildren finds teenagers want to know their genetic predisposition to disease, LiveScience reports.

More and more universities are helping their researchers patent their inventions, the Los Angeles Times reports.

Cancer Research UK unveils seven 'grand challenges' that it will fund researchers to tackle.